Member Info for Moneymunch

Microsaic are a tiny company, c£3m cash in the bank with a market cap of only c£7m , and so successful trials of their technology and disclosure of their global biopharma partner will be a game changer. The two leading players in the market are Agilent Technologies ( who have a market cap of $22.5bn ) and Thermo Fischer, and interestingly enough Microsaic shared a stand at an exhibition with Quantum Analytics back in July, and Agilent are listed as a customer on the Quantum website, and the US listed Agilent also have an office in Wokingham which isn't a million miles from Woking....and so a good chance Microsaic's global partner could be Agilent imho...there customers include all and sundry including every major pharma, and so if Microsaic's technology was integrated into agilent's, then the sky would be the limit.....in the meantime, i'm expecting the sp to continue its upward momentum as it re-rates and re-rates in anticipation Gl ;-) Agilent Technologies is an American public research, development and manufacturing company established in 1999 as a spin-off from Hewlett-Packard. The resulting IPO of Agilent stock was the largest in the history of Silicon Valley at the time.[6][7] The company provides analytical instruments, software, services and consumables for the entire laboratory workflow.[8] Agilent focuses its products and services on six markets: food, environmental and forensics, pharmaceutical, diagnostics, chemical and energy, and research. https://www.agilent.com/home

Cheers, and a bit more. Gl ;-) Just imagine the upside on confirmation of successful trials and disclosure of Microsaic's global biopharma partner with it's "global reach".....a multi-bag in the making this coming year. Gla ;-) "I think perhaps the most important aspect of that phase was that we had substantial end-user validation from big pharma and just to say that these are end-users whom our partner has very good global reach. What this new phase is it will bring more end-user validation to the approach, but I think the exciting deliverable is that we’ll be able to provide a lot more technical integration with the partner’s product." 28/12/17 Global Mass Spectrometry Market Is Expected to Reach US$9.99 Bn by the End of 2024 Transparency Market Research Report Added "Mass Spectrometer Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024" Albany, NY -- (SBWIRE) -- 12/28/2017 -- With a highly consolidated nature, the global mass spectrometry market was led by Agilent Technologies, Thermo Fisher Scientific, Inc., and Shimadzu Corporation in 2015. Their collective share in the market's value for the year was close to 49%, revealing a very low scope of growth for smaller players at the current rate. Advancements in Mass Spectrometry Open New Doors "What drives the global mass spectrometry market at the present moment is the original scope of application of these systems, coupled with the new possibilities that are entering the market simultaneously. One of the more recent examples of technological advancements in mass spectrometry is the adoption of matrix-associated laser desorption ionization imaging mass spectrometry, or MALDI-IMS. This system allows for the examination and analysis of tissues from a diagnostic perspective and thus reduces the overall time required for complete analysis of the sample. Another recent development is the high-resolution accurate mass system, which can detect as well as deliver simultaneously a higher resolution of the full product ion spectrum and mass accuracy. These systems are expected to usher in a new era of mass spectrometry," states a TMR analyst. The global mass spectrometry market is also being driven by the growing use of these equipment in the industries of pharmaceuticals, life sciences, and other clinical analytics. On the competitive side, the market is being favored in overall growth by the significant mergers and acquisitions that have occurred over the past decade, which includes the acquisition of Active Spectrum, Inc., by Bruker. Read more: http://www.digitaljournal.com/pr/3607574#ixzz52pLhEahY

So, I suppose the punchline here is really what pharma is looking for is very much real-time, powerful analysis that’s needed in many access points across the process, in raw incoming goods, the upstream in sold drug production and downstream purification. All of these areas represent a potential commercial entry point for us, traditional technologies just don’t have the power for that sort of high structural confirmation I was just talking about. What we’re doing is bringing our powerful detection both at at-line and on-line to provide immediate piece of mind. Just finally, we’re able to do that because we have a very unique all-in-one small footprint, in other words unlike contemporary mass spectrometry, we’ve got no need for cumbersome external pumps and external PC’s and it truly is a point of use mass detector with very easy maintenance and ease of use.

Q4: Why are you seeing the need for in-process mass spectrometry for biologics that you perhaps weren’t seeing for traditional drugs? A4: I think that’s the key question and it really is where the true benefit of mass spectroscopy for bioprocessing to be seen and I think it’s quite a detailed response actually. So, I often compare the two, the biologics and the traditional. If you look at traditional small molecule pharmaceuticals, they’ve got a comparatively simple structure, they’ve also got very well-defined production methods and what it means, in essence, is that these drugs are relatively insensitive to change. The difficulty we see with biologics goes back to how these drugs are manufactured by cells and the drugs structure or complexity, they’re very large molecules often being 30,000 atoms in size versus 30 for a small traditional drug. The complex structure is very sensitive even for the smallest change in a host of different factors and these can include really anything from manufacturing parameters, differences in raw materials, storage. Even then, when you think you’ve got it defined, unwanted unknowns may introduce problems with the final product or actually with the still very high value intermediary products. Slight changes in structure of the biologic renders them useless or they can actually be potentially lethal and also, any harmful contaminates such as the remnants of the host cell protein can also cause a really nasty and often lethal immune response. So, it’s really because of these risks that when the FDA grants their biologic licence to a biopharma company, they not only have to consider the product but also the process and the equipment so it’s really much wider than you would consider for a traditional drug. I think in recognition of this task, what the FDA does is to provide guidance of what it calls ‘Quality by Design’ or QbD and that covers four areas and these areas are actually very important for us. It covers four areas, that is the drug’s critical quality attributes to make sure that they meet key physical chemical and biological attributes of the drug itself. The second is that the drug companies identify the critical material attributes the incoming materials, the third is that the manufacturing process conforms to critical process and then that there is a relationship between that whole lot. In other words, basically what the FDA is saying is that things can’t be left to chance.

Q3: Can you give us a bit more background on the biologics market? A3: There is a whole wealth of published material out there actually, but I can draw on a recent report that Deloitte estimate that by about the year 2019, biologics revenue in itself is going to earn the pharmaceutical market about $400 billion. That represents about a third of the annual income of the pharma market and I think it’s especially interesting because the term ‘biologic’ was actually relatively unknown even twenty years. I think to put that into perspective, I can draw on a recent interview with a chap called Andrew Skibo, he’s MedImmune’s Head of Global Biologics Operations and Engineering, he states that across the industry as a whole, there’s around $20 million worth of biopharma site installs either in planning or underway. Now, if you consider the cost of a new biologics plant can range from anywhere from 1/10 to $0.5 million and take over 5 years to fully implement, you can see that pharma sees an appreciable return on what stands to be obviously a significant level of investment. For Microsaic Systems, what that means is that obviously the new installs are very interesting to us as a multiple-unit opportunity, actually in both current and future biological installations and this represents our target market.

Q2: Now, you touched on biopharmaceuticals in your last interview, can you explain to us what is a biopharmaceutical? A2: Biopharmaceuticals represent one of the most promising frontiers in medicine, they are also known formally as biological medical products or biologics. I think one of the key things that sets them apart from, say, traditional drugs is that they’re produced by genetically-engineered cells such as yeast and bacteria, very much in the same way as a home-brew kit and that sets them apart from traditional chemical synthesis. Biologics themselves, they’re composed of sugars, proteins, nucleic acids or a combination of substances or increasingly, and in the future, actually living cells and tissues so really quite incredible. They often actually large proteins, they’re very complex but specific structure and that structure is specifically designed to target disease. Their uses range from diseases like psoriasis through to oncology and perhaps the most famous of the latter is the highly-successful treatment for breast cancer, Trastuzumab or Herceptin. That was developed quite a while ago in 1998 by Genentech and UCLA but actually interestingly is now on the World Health Organisation’s list of essential medicines. I think what really sets them apart, aside from how they’re made, is while there’s extremely good efficacy the biologics specificity also drastically reduces unwanted side effects or adverse drug reactions, ADR’s as we call them. It’s estimated that those cost the US alone in excess of $100 billion annually and I guess it’s a sad case that figure is driven through about 2 million instances of ADR’s per annum in the US and tragically 100,000 deaths. As a matter of fact, the Centre for Education and Research on Therapeutics has put a figure on this as being the fourth largest killer in the US, ahead of pulmonary disease, diabetes, Aids and pneumonia, so it really is quite significant.

13th December 2017 Q&A with Glenn Tracey Chief Executive Officer at Microsaic Systems PLC (LON:MSYS) Microsaic Systems plc Q&A with Glenn Tracey Chief Executive Officer at Microsaic Systems PLC (LON:MSYS) Microsaic Systems PLC (LON:MSYS) Chief Executive Officer Glenn Tracey caught up with ************* for an exclusive interview to discuss the research agreement with a global biopharma partner, the meaning of a biopharmaceutical, the biologics market and why they are seeing the need for in-process mass spectrometry for biologics that perhaps they wouldn’t see for traditional drugs. Q1: Microsaic recently announced the signing of a research agreement with a global partner in biopharma, can you tell us a little bit more about that? A1: Yes, absolutely so I’ve got to say that we are under strict NDA in this particular case but what I can do is give you some context. Earlier in the year we successfully completed a significant joint feasibility phase to show dedicated at-line mass spec can assess the quality of biologics during the manufacture. I think perhaps the most important aspect of that phase was that we had substantial end-user validation from big pharma and just to say that these are end-users whom our partner has very good global reach. What this new phase is it will bring more end-user validation to the approach, but I think the exciting deliverable is that we’ll be able to provide a lot more technical integration with the partner’s product. So, should this activity be successful, it will take us into the second half of 2018 and then that will proceed a period of productisation. As I said, I can’t give any details yet about the size and timeline for commercialisation, but the opportunity is significant to us, to Microsaic, and delivery is proportionate, I would say, to our timescales.

No problem, the interview was first posted by Blueshoes7 on Adfvn, and definitely highlights Msys's stunning potential, i've picked up £20k's worth so far and nicely in profit....and more to come. .....£4m cash in the bank, only 181m shares in issue with the majority held by major investors....Gla ;-)

https://www.directors talkinterviews.com/interview-microsaic-systems-plc-agreement-global-partner/412742270

https:// www.***************************/interview-microsaic-systems-plc-agreement-global-partner/412742270

Interview Posted Friday With CEO Glenn Tracey. Microsaic Systems plc Agreement with Global Partner CEO Glenn Tracey joins ************* to discuss the signing of a research agreement with a global partner in biopharma. Glenn provides us with some background to the deal, explains what a biopharmaceutical is, talks about the value of the biologics market and tells us why they are seeing the need for in-process mass spectrometry for biologics that perhaps wouldn’t see for traditional drugs. https://www.***************************/interview-microsaic-systems-plc-agreement-global-partner/412742270 Around 1.30 he confirms it is a SIGNIFICANT Opportunity. Nice

Insight into these conjugates is critical to making accurate predictions regarding future oil and gas potential; since 1980, Africa's proven reserves of natural gas have risen over 140 per cent, due in large part to accurate assessment of conjugate data. "As clearly illustrated by recent exploration and production activity and the accelerated pace of drilling, Namibia has become an important exploration province, attracting oil companies worldwide," said Joe Gagliardi, senior vice president of ION's GeoVentures group. "In conjunction with existing and planned BasinSPAN surveys in adjacent countries, NamibiaSPAN should help lift offshore activity in one of the world's most important regions for oil and gas production." Data processing and imaging is currently underway, with pre-stack time migration (PSTM) data scheduled for availability by July 2015 and pre-stack depth migration (PSDM) data available by October 2015.

Wouldn't be surprised if the following report was the catalyst for last weeks stellar rise.......Repsol had better hurry or the Chinese might make a move. GLA Holders ;-) ION Geophysical boosts seismic data library offshore Namibia Submitted by Editorial staff on 25th March 2015 ION Geophysical has announced completion of the seismic acquisition stage of the company's NamibiaSPAN programme, which extends the full length of Namibia's offshore continental margin Acquisition was conducted in cooperation with BGP (China National Petroleum Corporation). With an estimated 100 billion barrels of oil remaining to be discovered and produced in Africa's offshore waters, NamibiaSPAN plays a critical role in establishing a contiguous dataset for the full West Africa margin extending from Mossel Bay to the Bight of Benin. NamibiaSPAN comprises over 10,000 kilometres of two-dimensional (2D) multi-client data and represents the newest addition to ION's BasinSPAN library, which encompasses approximately 500,000 kilometres of 2D basin-scale data in E&P hotspots around the world including NigeriaSPAN, EquatorSPAN and CongoSPAN in West Africa. "Namibia is positioned to help define future exploration and production activity across a wide region that extends beyond our borders," said Immanuel Mulunga, petroleum commissioner for Namibia's Ministry of Mines and Energy. "Our goal is to achieve the fullest understanding of Namibia's offshore potential, which includes tying our seismic data with that of neighbouring basins in order to better comprehend the margin as a whole." NamibiaSPAN enhances interpretation of its conjugate margin in the Pelotas Basin offshore Brazil, with conjugate ties extending to Uruguay and Argentina. Using recently acquired BasinSPAN data in South America, geoscientists can deploy conjugate exploration strategies to evaluate rock and sedimentary connections as these regions evolved and separated over time.

when a share hits rock bottom, it's the best time to buy, so good luck!

hope you are too!!! I think a few are missing you, from you know where???? Iv'e had Asmon my watch list for a while, and obviously had a lucky escape....and sorry to those who've lost out. I read the Times article this morning but don't subscribe on-line so can't post it in full.....but they obviously think they're after the cash assests of the company as opposed to any real interest in the pipeline........"the drug developer with a string of drugs that don't work".....

Miller’s tale sets investors rushing to buy into a big takeover story Gary Parkinson The TimesPublished: 03 February 2011Markets ...investment bank Evolution, declared a 10.8 per cent stake in Antisoma, the drug developer that has developed a string of drugs that...shareholder value, it would be no surprise if he pushed for Antisoma to be wound up to release its remaining £23.4 million of...